NT KC 005Alternative Names: NTKC005
Latest Information Update: 22 Feb 2016
At a glance
- Originator Neurotec Pharma
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Stroke
Most Recent Events
- 22 Feb 2016 NT KC 005 is still in preclinical phase trials for Stroke in Spain (Neurotec Pharma pipeline, February 2016)